In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Open Access
- 8 February 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (3) , 473-477
- https://doi.org/10.1093/jac/dkl512
Abstract
Colistin is being increasingly used for treatment of infections caused by multidrug-resistant Gram-negative bacteria, including Acinetobacter baumannii. The in vitro pharmacodynamic properties of colistin (sulphate) were investigated by studying the time–kill kinetics and the post-antibiotic effect (PAE) against multidrug-resistant, including colistin heteroresistant, A. baumannii. Time–kill was studied with four multidrug-resistant clinical isolates at concentrations ranging from 0.5 to 64 × MIC. The PAE was examined after 20 min exposure with five clinical isolates, including the four in the time–kill study, plus ATCC 19606. Colistin showed extremely rapid killing in a concentration-dependent manner; but re-growth was observed as early as 3 h and substantial re-growth at 24 h even at concentrations up to 32 × MIC or 64 × MIC for some isolates. Colistin exhibited modest PAE of 1.0, 2.3 and 3.5 h at 16, 32 and 64 × MIC, respectively, against ATCC 19606. Surprisingly, negative PAE (range: –0.8 to –8.15 h) was observed for all of the five clinical isolates. These findings suggest that monotherapy with colistin methanesulphonate, the parenteral form of colistin, and long dosage intervals (e.g. 24 h) may be problematic for treatment of infections caused by colistin heteroresistant A. baumannii.Keywords
This publication has 20 references indexed in Scilit:
- Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infectionsThe Lancet Infectious Diseases, 2006
- Old Polymyxins Are Back: Is Resistance Close?Clinical Infectious Diseases, 2006
- Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2006
- Multidrug-ResistantAcinetobacterExtremity Infections in SoldiersEmerging Infectious Diseases, 2005
- Evaluation of colistin as an agent against multi-resistant Gram-negative bacteriaPublished by Elsevier ,2004
- Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside usePediatric Pulmonology, 2004
- Multidrug-Resistant Acinetobacter Infections: An Emerging Challenge to CliniciansAnnals of Pharmacotherapy, 2004
- The need for new antibioticsClinical Microbiology & Infection, 2004
- The threat from the pink cornerAnnals of Medicine, 2003
- Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological featuresClinical Microbiology Reviews, 1996